Search

everythinglearnresearchcommunity

for

Search:↓

A user named "Redbone2222" shares their positive experience with a hair transplant procedure of 2500-3000 grafts, along with the use of 1mg finasteride daily and 5% topical minoxidil. They express satisfaction with the results and believe that finasteride has been more effective for them than minoxidil.

The conversation discusses GT20029 as a potential hair loss treatment that could act like a cure by targeting androgen receptors in scalp hair follicles. Specific treatments mentioned include GT20029, with a user expressing hope that it could make male pattern baldness obsolete.

The user is considering a hair transplant to increase hair density after using finasteride and minoxidil for two years. They prefer a natural hairline and are unsure if a transplant is suitable for overall thinning.

A 25-year-old man had a 3500 graft hair transplant on the frontal region and is happy with the results after 8 months. He has been on minoxidil and finasteride, switched to dutasteride, added ketoconazole shampoo for seborrheic dermatitis, and is considering a second transplant for the mid scalp/crown.

A 28-year-old man is considering whether to proceed with a hair transplant in February or continue using oral minoxidil, finasteride, and dermastamping, which have shown great progress in 3.5 months, to achieve desired results by his wedding in September 2026. Most responses suggest postponing the transplant to avoid potential "shock loss" and relying on the current treatment and hair fibers for the wedding.

Ibrox1972 shared an 8.5-month update on their 2,689-graft hair transplant by Dr. Raghu Reddy in London, along with using oral finasteride, oral minoxidil, and microneedling. Users praised the natural-looking results and discussed the importance of choosing a skilled doctor.

AnagenInc is ready to produce a hair loss treatment called GT20029 if there is enough demand. People are discussing combining it with other treatments like finasteride and minoxidil, and some are concerned about the legitimacy and safety of gray market products.

Kintor Pharma has started a Phase II trial in China for GT20029, a potential new treatment for hair loss. Participants are discussing the significance, potential release dates, and comparing it to other treatments and technologies like stem cell hair transplants and SAMIRNA.

A user shared their hair transformation over four months using daily 2.5mg oral minoxidil, every other day 1mg oral finasteride, weekly dermastamping, and daily scalp massages, with plans for a hair transplant. Another user suggested continuing the medication for a year before considering a transplant.

The user had a hair transplant in 2021 with 1600 grafts and is currently using finasteride, minoxidil, biotin, and collagen. They are considering another transplant in Turkey to address a bald spot and improve coverage in the front and middle.

The conversation is about the potential release of GT20029 on the grey market and concerns about its safety and authenticity. One user advises waiting for the official release by Kintor.

The conversation is about hair loss treatments, specifically the anticipation for the release of a new treatment, GT20029, by 2028. Users are discussing their experiences with current treatments like finasteride and dutasteride, and the potential of future treatments, including FAK inhibitors and verteporfin trials.

GT20029 is discussed as a potential treatment for androgenetic hair loss by targeting androgen receptors, unlike finasteride which reduces DHT broadly. Concerns include its effectiveness, genetic variations in androgen receptors, and availability, with some skepticism about its potential as a true alternative.

Transitioning genders humorously suggested for hair regrowth, noting some transgender individuals experience this. Discusses treatments like minoxidil, finasteride, and hormone therapy, but advises against transitioning solely for hair regrowth.

A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.

The post is about a user sharing their hair transplant results after 2.5 years. They did not use any medications like finasteride or minoxidil.

Hair transplantation involves a detailed consultation, preparation, and a long-term recovery process with stages like initial shedding and gradual new hair growth over months. Setting realistic expectations is crucial for patient satisfaction.

The conversation is about the difficulty in obtaining GT20029, a hair loss treatment, due to patent issues and the need to resort to group buys or Chinese labs for acquisition. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.

The user shared progress pictures after 4.5 months of using 0.5 mg finasteride and 2.5 mg minoxidil daily for hair loss, considering increasing the finasteride dose after 6 months. Some attribute the improvement to the hair transplant, while others inquire about changes in crown density.

Pelage plans to conduct two Phase 3 trials for PP405, a new hair loss treatment, which may take about a year to complete. Users discuss various hair loss treatments, including pyrilutamide, minoxidil, finasteride, and clascoterone, with some expressing impatience over the lengthy trial process compared to faster drug approvals like the COVID vaccine.

A user shared their experience with a second hair transplant by Dr. Gokhan Gur, focusing on the midscalp and crown with 1849 grafts. Their current treatment includes dutasteride, finasteride, oral and topical minoxidil, and Nizoral shampoo.

The conversation is about the availability of the research chemical GT20029 for hair loss treatment and when companies like Anageninc will have it. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

A 22-year-old trans woman has been on 6mg estradiol enanthate for five months. She reports thicker and healthier hair but not much regrowth yet.

PP405 shows significantly better early-stage hair regrowth results compared to minoxidil and finasteride, with 31% of users experiencing over 20% density increase in 4–8 weeks. Minoxidil and finasteride show minimal or no visible regrowth in the same timeframe.

The user's consideration of taking finasteride as a short-term treatment, while awaiting advances in medical technology such as Pyrilutamide and GT20029; other users' experiences with Finasteride, including potential side effects.

GT20029 is a potential treatment for androgenetic alopecia, addressing the root cause by targeting androgen receptors, unlike Minoxidil or Finasteride. It is seen as a preventative measure rather than a regrowth agent, with hopes for market release soon.

GT20029 and pyrilutamide are both androgen antagonists but work differently; GT20029 degrades the androgen receptor, while pyrilutamide blocks DHT from binding. GT20029 is expected to have similar efficacy to CosmeRNA.

A user discussing their hair transplant progress at 8 months, expressing concern about lack of growth in the front. They're currently using Minoxidil and dutasteride, and considering microneedling. The responses suggest waiting for full growth, which can take up to 13-14 months.

Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.